Advertisement

Meta-Analysis of Randomized Trials of Glycoprotein IIb/IIIa Inhibitors in High-Risk Acute Coronary Syndromes Patients Undergoing Invasive Strategy

      It is still unknown whether upstream administration of glycoprotein (Gp) IIb/IIIa inhibitors, aiming at cooling the culprit lesion before angioplasty, is superior to its selective downstream administration in high-risk patients with acute coronary syndromes (ACSs) undergoing coronary angioplasty. Therefore, the aim of the present study was to perform a meta-analysis of randomized trials comparing upstream to downstream administration of Gp IIb/IIIa inhibitors in high-risk patients with ACS undergoing early invasive strategy. We obtained results from all randomized trials on this issue. The literature was scanned by formal searches of electronic databases from January 1990 to March 2010. The following key words were used: “randomized trial,” “myocardial infarction,” “ACS,” “coronary angioplasty,” “upstream,” “downstream,” “Gp IIb/IIIa inhibitors,” “abciximab,” “tirofiban,” and “eptifibatide.” Primary and secondary clinical end points were mortality and myocardial infarction at 30 days, respectively. Major bleeding complications were assessed as a safety end point. Seven randomized trials were included in the meta-analysis, involving 19,929 patients (9,981 or 50.0% in the upstream Gp IIb/IIIa inhibitors group and 9,948 or 50% in the downstream Gp IIb/IIIa inhibitors group). Upstream Gp IIb/IIIa inhibitors did not decrease 30-day mortality (2.0% vs 2.0%, p = 0.84) or recurrence of myocardial infarction (7.0% vs 7.6%, p = 0.11) but were associated with higher risk of major bleeding complications (1.8% vs 1.3%, p = 0.0002). In conclusion, this meta-analysis shows that in high-risk patients with ACS undergoing an early invasive strategy, upstream administration of Gp IIb/IIIa inhibitors does not improve clinical outcome compared to a downstream selective administration, and it is associated with an increased risk of major bleeding complications. Therefore, a strategy of upstream Gp IIb/IIIa inhibitors cannot be recommended.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Anderson J.L.
        • Adams C.D.
        • Antman E.M.
        • Bridges C.R.
        • Califf R.M.
        • Casey Jr, D.E.
        • Chavey II, W.E.
        • Fesmire F.M.
        • Hochman J.S.
        • Levin T.N.
        • Lincoff A.M.
        • Peterson E.D.
        • Theroux P.
        • Wenger N.K.
        • Wright R.S.
        • Smith Jr, S.C.
        • Jacobs A.K.
        • Adams C.D.
        • Anderson J.L.
        • Antman E.M.
        • Halperin J.L.
        • Hunt S.A.
        • Krumholz H.M.
        • Kushner F.G.
        • Lytle B.W.
        • Nishimura R.
        • Ornato J.P.
        • Page R.L.
        • Riegel B.
        ACC/AHA 2007 guidelines for the management of patients with unstable angina/non–ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine.
        J Am Coll Cardiol. 2007; 50 (erratum. J Am Coll Cardiol 2008;51:974): e1-e157
        • Bassand J.P.
        • Hamm C.W.
        • Ardissino D.
        • Boersma E.
        • Budaj A.
        • Fernández-Avilés F.
        • Fox K.A.
        • Hasdai D.
        • Ohman E.M.
        • Wallentin L.
        • Wijns W.
        Guidelines for the diagnosis and treatment of non–ST-segment elevation acute coronary syndromes.
        Eur Heart J. 2007; 28: 1598-1660
        • The Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators
        A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina.
        N Engl J Med. 1998; 338: 1498-1505
        • The Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators
        Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non–Q-wave myocardial infarction.
        N Engl J Med. 1998; 338: 1488-1497
        • The PURSUIT Trial Investigators
        Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes.
        N Engl J Med. 1998; 339: 436-443
        • Boersma E.
        • Harrington R.A.
        • Moliterno D.J.
        • White H.
        • Théroux P.
        • Van de Werf F.
        • de Torbal A.
        • Armstrong P.W.
        • Wallentin L.C.
        • Wilcox R.G.
        • Simes J.
        • Califf R.M.
        • Topol E.J.
        • Simoons M.L.
        Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials.
        Lancet. 2002; 359: 189-198
        • Moher D.
        • Cook D.J.
        • Eastwood S.
        • Olkin I.
        • Rennie D.
        • Stroup D.F.
        Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement.
        Lancet. 1999; 354: 1896-1900
        • Bolognese L.
        • Falsini G.
        • Liistro F.
        • Angioli P.
        • Ducci K.
        • Taddei T.
        • Tarducci R.
        • Cosmi F.
        • Baldassarre S.
        • Burali A.
        Randomized comparison of upstream tirofiban versus downstream high bolus dose tirofiban or abciximab on tissue-level perfusion and troponin release in high-risk acute coronary syndromes treated with percutaneous coronary interventions: the EVEREST trial.
        J Am Coll Cardiol. 2006; 47: 522-528
        • Durand E.
        • Hamm C.W.
        • Macaya C.M.
        • Georges J.L.
        • Coste P.
        • Wolf J.E.
        • Slama M.S.
        • Husted S.E.
        • Mosseri M.
        • Lafont A.
        A randomised controlled trial of upstream administration of eptifibatide in patients presenting non–ST segment elevation acute coronary syndrome treated with an invasive strategy.
        EuroIntervention. 2007; 3: 228-234
        • Giugliano R.P.
        • Newby L.K.
        • Harrington R.A.
        • Gibson C.M.
        • Van de Werf F.
        • Armstrong P.
        • Montalescot G.
        • Gilbert J.
        • Strony J.T.
        • Califf R.M.
        • Braunwald E.
        • EARLY ACS Steering Committee
        The Early Glycoprotein IIb/IIIa Inhibition in Non–ST-Segment Elevation Acute Coronary Syndrome (EARLY ACS) trial: a randomized placebo-controlled trial evaluating the clinical benefits of early front-loaded eptifibatide in the treatment of patients with non–ST-segment elevation acute coronary syndrome—study design and rationale.
        Am Heart J. 2005; 149: 994-1002
        • Leoncini M.
        • Toso A.
        • Maioli M.
        • Bellandi F.
        • Badia T.
        • Politi A.
        • De Servi S.
        • Dabizzi R.P.
        Effects of tirofiban plus clopidogrel versus clopidogrel plus provisional abciximab on biomarkers of myocardial necrosis in patients with non–ST-elevation acute coronary syndromes treated with early aggressive approach.
        Am Heart J. 2005; 150: 401-406
        • Liu T.
        • Xie Y.
        • Zhou Y.J.
        • Li Y.P.
        • Ma H.Y.
        • Guo Y.H.
        • Liu Y.Y.
        • Zhao Y.X.
        • Shi D.M.
        Effects of upstream tirofiban versus downstream tirofiban on myocardial damage and 180-day clinical outcomes in high-risk acute coronary syndromes patients undergoing percutaneous coronary interventions.
        Chin Med J. 2009; 122: 1732-1737
        • Neumann F.J.
        • Kastrati A.
        • Pogatsa-Murray G.
        • Mehilli J.
        • Bollwein H.
        • Bestehorn H.P.
        • Schmitt C.
        • Seyfarth M.
        • Dirschinger J.
        • Schömig A.
        Evaluation of prolonged antithrombotic pretreatment (“cooling-off” strategy) before intervention in patients with unstable coronary syndromes: a randomized controlled trial.
        JAMA. 2003; 290: 1593-1599
        • Roe M.T.
        • Christenson R.H.
        • Ohman E.M.
        • Bahr R.
        • Fesmire F.M.
        • Storrow A.
        • Mollod M.
        • Peacock W.F.
        • Rosenblatt J.A.
        • Yang H.
        • Fraulo E.S.
        • Hoekstra J.W.
        • Gibler W.B.
        • EARLY Investigators; Emergency Medicine Cardiac Research and Education Group
        A randomized, placebo-controlled trial of early eptifibatide for non–ST-segment elevation acute coronary syndromes.
        Am Heart J. 2003; 146: 993-998
        • Stone G.W.
        • Bertrand M.E.
        • Moses J.W.
        • Ohman E.M.
        • Lincoff A.M.
        • Ware J.H.
        • Pocock S.J.
        • McLaurin B.T.
        • Cox D.A.
        • Jafar M.Z.
        • Chandna H.
        • Hartmann F.
        • Leisch F.
        • Strasser R.H.
        • Desaga M.
        • Stuckey T.D.
        • Zelman R.B.
        • Lieber I.H.
        • Cohen D.J.
        • Mehran R.
        • White H.D.
        • ACUITY Investigators
        Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY Timing Trial.
        JAMA. 2007; 297: 591-602
        • van't Hof A.W.
        • de Vries S.T.
        • Dambrink J.H.
        • Miedema K.
        • Suryapranata H.
        • Hoorntje J.C.
        • Gosselink A.T.
        • Zijlstra F.
        • de Boer M.J.
        A comparison of two invasive strategies in patients with non–ST elevation acute coronary syndromes: results of the Early or Late Intervention in unStable Angina (ELISA) pilot study.
        Eur Heart J. 2003; 24: 1401-1405
        • Rasoul S.
        • Ottervanger J.P.
        • de Boer M.J.
        • Miedema K.
        • Hoorntje J.C.
        • Gosselink M.
        • Zijlstra F.
        • Suryapranata H.
        • Dambrink J.H.
        • van't Hof A.W.
        A comparison of dual vs. triple antiplatelet therapy in patients with non–ST-segment elevation acute coronary syndrome: results of the ELISA-2 trial.
        Eur Heart J. 2006; 27: 1401-1407
        • Wiviott S.D.
        • Braunwald E.
        • McCabe C.H.
        • Montalescot G.
        • Ruzyllo W.
        • Gottlieb S.
        • Neumann F.J.
        • Ardissino D.
        • De Servi S.
        • Murphy S.A.
        • Riesmeyer J.
        • Weerakkody G.
        • Gibson C.M.
        • Antman E.M.
        • TRITON-TIMI 38 Investigators
        Prasugrel versus clopidogrel in patients with acute coronary syndromes.
        N Engl J Med. 2007; 357: 2001-2015
        • Wallentin L.
        • Becker R.C.
        • Budaj A.
        • Cannon C.P.
        • Emanuelsson H.
        • Held C.
        • Horrow J.
        • Husted S.
        • James S.
        • Katus H.
        • Mahaffey K.W.
        • Scirica B.M.
        • Skene A.
        • Steg P.G.
        • Storey R.F.
        • Harrington R.A.
        • Freij A.
        • Thorsén M.
        • PLATO Investigators
        Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
        N Engl J Med. 2009; 361: 1045-1057